Axsome Therapeutics Inc.
Axsome Therapeutics Settles Sunosi Patent Litigation with Hikma Pharmaceuticals
Summary
On March 5, 2025, Axsome Therapeutics, Inc. announced a settlement agreement with Hikma Pharmaceuticals USA, Inc., resolving patent litigation related to Axsome's product Sunosi (solriamfetol). Under the terms of the settlement, Axsome will grant Hikma a license to sell a generic version of Sunosi, subject to FDA approval and certain conditions. The settlement is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice. Similar litigation with other parties remains pending.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement